原發性膽汁性膽管炎治療市場 - 按藥物（熊去氧膽酸、奧貝膽酸）、用途（人類、獸醫）、配銷通路（醫院藥房、藥房和零售藥房、在線藥房） - 全球預測（ 2024 - 2032）

在肝病盛行率上升的推動下，2024-2032 年原發性膽汁性膽管炎治療市場規模將以 7.1% 的複合年成長率成長。根據 IJPCA 的數據，肝病約佔全球死亡人數的 4%，每年約有 200 萬人死亡。由於人口老化、不健康的生活方式和代謝紊亂發病率增加等因素，包括原發性膽汁性膽汁性膽汁性肝病（PBC）在內的肝病變得越來越常見。由於 PBC 是一種慢性進行性肝臟疾病，因此持續的醫療照護和管理至關重要。它促使醫療保健提供者和製藥公司加大研發投資，以推出新的有效治療方案。

聯合療法的發展有利於產業前景。聯合療法可以同時針對疾病的不同方面，可能比單一療法更有效地減少 PBC 的進展。隨著越來越多的資料支持聯合治療的益處，預計聯合治療的採用將會增加，從而促進市場成長。

原發性膽汁性膽管炎治療產業根據藥物、用途、配銷通路和地區進行分類。

到 2032 年，奧貝膽酸部分將獲得顯著的吸引力，因為它在減緩疾病進展和改善肝功能方面顯示出顯著功效。該藥物透過活化法尼醇 X 受體 (FXR) 發揮作用，該受體在膽汁酸調節和發炎中發揮著至關重要的作用。 OCA 的成功促使正在進行的臨床試驗和研究探索其聯合療法的潛力及其對其他肝臟疾病的有效性，從而提高了該細分市場的佔有率。

由於便利性、可近性和成本較低，到 2032 年，線上藥局市場將實現穩定成長。此管道對於患有原發性膽汁性膽管炎（PBC）等慢性病的患者特別有益，因為他們需要定期補充藥物和進行監測。線上平台提供全面的藥物資訊、病患評論和送貨上門服務，提高病患對處方治療的依從性。 COVID-19 大流行進一步加速了向數位健康解決方案的轉變，越來越多的患者選擇在線藥房以避免在實體藥房環境中潛在的暴露。

在肝病高盛行率和完善的醫療基礎設施的推動下，歐洲原發性膽汁性膽管炎治療產業規模將在 2024 年至 2032 年快速擴張。領先製藥公司的存在、廣泛的研究活動以及支持罕見疾病治療的有利政府政策是推動歐洲市場的關鍵因素。此外，該地區對個人化醫療的關注和先進治療解決方案的採用也促進了對 PBC 治療的需求不斷成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 原發性膽汁性膽管炎盛行率上升
    • 增加患者對非侵入性治療的偏好
    • 研發活動數量不斷增加
    • 診斷技術不斷進步
  • 產業陷阱與挑戰
    • 缺乏治癒性治療
    • 醫療保健提供者和患者的認知有限
• 成長潛力分析
• 定價分析
• 未來市場趨勢
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥品分類，2021 - 2032 年

• 主要趨勢
• 熊去氧膽酸
• 奧貝膽酸
• 其他藥品

第 6 章：市場估計與預測：按用途分類，2021 - 2032 年

• 主要趨勢
• 人類
• 獸醫

第 7 章：市場估計與預測：按配銷通路，2021 - 2032

• 主要趨勢
• 醫院藥房
• 藥局和零售藥局
• 網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• Arlak Biotech Pvt. Ltd
• Cadila Pharmaceuticals
• Drag Pharma
• Gilead Sciences, Inc.
• Intercept Pharmaceuticals, Inc.
• Ipsen
• Leeford Healthcare Limited
• Lupin
• Sun Pharmaceuticals Ltd.
• Viatris, Inc. (Mylan N.V.)
• Vivaldis

The Primary Biliary Cholangitis Therapeutics Market size will grow at 7.1% CAGR during 2024-2032, driven by the rising prevalence of liver diseases. According to IJPCA, liver diseases account for approximately 4% of all deaths globally, with around 2 million deaths occurring annually. Liver diseases, including PBC, are becoming more common due to factors such as aging populations, unhealthy lifestyles, and increasing rates of metabolic disorders. As PBC is a chronic and progressive liver condition, the need for ongoing medical care and management is paramount. It is prompting healthcare providers and pharmaceutical companies to invest more in R&D to introduce new and effective therapeutic options.

The development of combination therapies is favoring the industry outlook. Combination therapies allow targeting different aspects of the disease simultaneously, potentially reducing the progression of PBC more effectively than monotherapy. As more data supports the benefits of combination treatments, their adoption is expected to increase, thereby inducing market growth.

The primary biliary cholangitis therapeutics industry is classified based on drug, use, distribution channel, and region.

The obeticholic acid segment will gain significant traction through 2032, as it has shown significant efficacy in slowing disease progression and improving liver function. The drug works by activating the farnesoid X receptor (FXR), which plays a crucial role in bile acid regulation and inflammation. The success of OCA has prompted ongoing clinical trials and research to explore its potential in combination therapies and its effectiveness in other liver diseases, boosting the segment share.

The online pharmacies segment will witness steady growth through 2032, owing to the convenience, accessibility, and often lower costs. This channel is particularly beneficial for patients with chronic conditions like PBC, who require regular medication refills and monitoring. Online platforms offer comprehensive drug information, patient reviews, and home delivery services, enhancing patient adherence to prescribed therapies. The COVID-19 pandemic has further accelerated the shift towards digital health solutions, with more patients opting for online pharmacies to avoid potential exposure in physical pharmacy settings.

Europe primary biliary cholangitis therapeutics industry size will expand at a rapid pace over 2024-2032, driven by a high prevalence of liver diseases and a well-established healthcare infrastructure. The presence of leading pharmaceutical companies, extensive research activities, and favorable government policies supporting rare disease treatments are key factors driving the market in Europe. Additionally, the region's focus on personalized medicine and the adoption of advanced therapeutic solutions are contributing to the increasing demand for PBC treatments.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360º synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of primary biliary cholangitis
    • 3.2.1.2 Increasing patient preference for non-invasive treatment
    • 3.2.1.3 Growing number of research and development activities
    • 3.2.1.4 Increasing advancement in diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of curative treatment
    • 3.2.2.2 Limited awareness among healthcare providers and patients
• 3.3 Growth potential analysis
• 3.4 Pricing analysis
• 3.5 Future market trends
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Ursodeoxycholic acid
• 5.3 Obeticholic acid
• 5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Use, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Human
• 6.3 Veterinary

Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Drug store & retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Arlak Biotech Pvt. Ltd
• 9.3 Cadila Pharmaceuticals
• 9.4 Drag Pharma
• 9.5 Gilead Sciences, Inc.
• 9.6 Intercept Pharmaceuticals, Inc.
• 9.7 Ipsen
• 9.8 Leeford Healthcare Limited
• 9.9 Lupin
• 9.10 Sun Pharmaceuticals Ltd.
• 9.11 Viatris, Inc. (Mylan N.V.)
• 9.12 Vivaldis